Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

846 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tildrakizumab improves high burden skin symptoms, impaired sleep and quality of life of moderate-to-severe plaque psoriasis patients in conditions close to clinical practice.
Costanzo A, Llamas-Velasco M, Fabbrocini G, Cuccia A, Rivera-Diaz R, Gaarn Du Jardin K, Kasujee I, Puig L, Carrascosa JM. Costanzo A, et al. J Eur Acad Dermatol Venereol. 2023 Oct;37(10):2004-2015. doi: 10.1111/jdv.19229. Epub 2023 Jun 13. J Eur Acad Dermatol Venereol. 2023. PMID: 37246505
Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis.
Gisondi P, Altomare G, Ayala F, Bardazzi F, Bianchi L, Chiricozzi A, Costanzo A, Conti A, Dapavo P, De Simone C, Foti C, Naldi L, Offidani A, Parodi A, Piaserico S, Prignano F, Rongioletti F, Stingeni L, Talamonti M, Girolomoni G. Gisondi P, et al. Among authors: costanzo a. J Eur Acad Dermatol Venereol. 2017 May;31(5):774-790. doi: 10.1111/jdv.14114. Epub 2017 Feb 27. J Eur Acad Dermatol Venereol. 2017. PMID: 28244153
Evidence for a 'window of opportunity' in hidradenitis suppurativa treated with adalimumab: a retrospective, real-life multicentre cohort study.
Marzano AV, Genovese G, Casazza G, Moltrasio C, Dapavo P, Micali G, Sirna R, Gisondi P, Patrizi A, Dini V, Bianchini D, Bianchi L, Fania L, Prignano F, Offidani A, Atzori L, Bettoli V, Cannavò SP, Venturini M, Bongiorno MR, Costanzo A, Fabbrocini G, Peris K. Marzano AV, et al. Among authors: costanzo a. Br J Dermatol. 2021 Jan;184(1):133-140. doi: 10.1111/bjd.18983. Epub 2020 Apr 13. Br J Dermatol. 2021. PMID: 32119111 Free article.
Diagnosis and management of moderate to severe atopic dermatitis in adolescents. A Consensus by the Italian Society of Dermatology and Venereology (SIDeMaST), the Italian Association of Hospital Dermatologists and Public Health (ADOI), the Italian Association of Hospital and Territorial Allergists and Immunologists (AAIITO), the Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC), the Italian Society of Pediatric Allergy and Immunology (SIAIP), the Italian Society of Allergological, Occupational and Environmental Dermatology (SIDAPA), and the Italian Society of Pediatric Dermatology (SIDerP).
Calzavara-Pinton P, Belloni Fortina A, Bonamonte D, Marseglia GL, Miraglia Del Giudice M, Musarra A, Nettis E, Neri I, Patruno C, Stingeni L, Peris K; RADAR Group. Calzavara-Pinton P, et al. Ital J Dermatol Venerol. 2021 Apr;156(2):184-197. doi: 10.23736/S2784-8671.20.06654-7. Epub 2020 May 21. Ital J Dermatol Venerol. 2021. PMID: 32438781 Free article.
Brodalumab for the treatment of moderate-to-severe plaque-type psoriasis: a real-life, retrospective 24-week experience.
Fargnoli MC, Esposito M, Dapavo P, Parodi A, Rossi M, Tiberio R, Dastoli S, Offidani AM, Argenziano G, Gisondi P, Lo Schiavo A, Loconsole F, Pella P, Bardazzi F, Cusano F, Gattoni M, Nacca M, Cannavò SP, Pellegrini C, Costanzo A; BRILLIANT Working Group. Fargnoli MC, et al. Among authors: costanzo a. J Eur Acad Dermatol Venereol. 2021 Mar;35(3):693-700. doi: 10.1111/jdv.16931. Epub 2020 Oct 13. J Eur Acad Dermatol Venereol. 2021. PMID: 32916767
Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations.
Gisondi P, Talamonti M, Chiricozzi A, Piaserico S, Amerio P, Balato A, Bardazzi F, Calzavara Pinton P, Campanati A, Cattaneo A, Dapavo P, De Simone C, Dini V, Fargnoli MC, Flori ML, Galluzzo M, Guarneri C, Lasagni C, Loconsole F, Lo Schiavo A, Malagoli P, Malara G, Mercuri SR, Musumeci ML, Naldi L, Papini M, Parodi A, Potenza C, Prignano F, Rongioletti F, Stingeni L, Tiberio R, Venturini M, Bianchi L, Costanzo A, Cusano F, Girolomoni G, Offidani AM, Peris K. Gisondi P, et al. Among authors: costanzo a. Dermatol Ther (Heidelb). 2021 Feb;11(1):235-252. doi: 10.1007/s13555-020-00475-8. Epub 2021 Jan 11. Dermatol Ther (Heidelb). 2021. PMID: 33426634 Free PMC article.
Guselkumab: an anti-IL-23 antibody for the treatment of moderate-to-severe plaque psoriasis.
Chiricozzi A, Costanzo A, Fargnoli MC, Malagoli P, Piaserico S, Amerio P, Argenziano G, Balato N, Bardazzi F, Bianchi L, Carrera CG, Conti A, Dapavo P, De Simone C, Loconsole F, Lo Schiavo A, Malara G, Musumeci ML, Parodi A, Peris K, Prignano F, Rongioletti F, Talamonti M, Potenza C. Chiricozzi A, et al. Among authors: costanzo a. Eur J Dermatol. 2021 Feb 1;31(1):3-16. doi: 10.1684/ejd.2021.3965. Eur J Dermatol. 2021. PMID: 33648915 Review.
A real-world economic analysis of biologic therapies for moderate-to-severe plaque psoriasis in Italy: results of the CANOVA observational longitudinal study.
Zagni E, Bianchi L, Fabbrocini G, Corrao S, Offidani A, Stingeni L, Costanzo A, Pellacani G, Peris K, Bardazzi F, Argenziano G, Ruffolo S, Dapavo P, Carrera C, Fargnoli MC, Parodi A, Romanelli M, Malagoli P, Talamonti M, Megna M, Raspanti M, Paolinelli M, Hansel K, Narcisi A, Conti A, De Simone C, Chessa MA, De Rosa A, Provenzano E, Ortoncelli M, Moltrasio C, Fidanza R, Burlando M, Tonini A, Gaiani FM, Simoni L, Zullo A, Fiocchi M, Colombo D. Zagni E, et al. Among authors: costanzo a. BMC Health Serv Res. 2021 Sep 6;21(1):924. doi: 10.1186/s12913-021-06866-7. BMC Health Serv Res. 2021. PMID: 34488749 Free PMC article.
Real-world evidence of biologic treatments in moderate-severe psoriasis in Italy: Results of the CANOVA (EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: An obserVAtional longitudinal study of real-life clinical practice) study.
Colombo D, Bianchi L, Fabbrocini G, Corrao S, Offidani A, Stingeni L, Costanzo A, Pellacani G, Peris K, Bardazzi F, Argenziano G, Ruffolo S, Dapavo P, Carrera C, Fargnoli MC, Parodi A, Romanelli M, Malagoli P, Talamonti M, Megna M, Raspanti M, Paolinelli M, Hansel K, Narcisi A, Conti A, De Simone C, Chessa MA, De Rosa A, Provenzano E, Ortoncelli M, Moltrasio C, Fidanza R, Burlando M, Tonini A, Gaiani FM, Simoni L, Ori A, Fiocchi M, Zagni E. Colombo D, et al. Among authors: costanzo a. Dermatol Ther. 2022 Jan;35(1):e15166. doi: 10.1111/dth.15166. Epub 2021 Nov 23. Dermatol Ther. 2022. PMID: 34676662
Long-term management of moderate-to-severe adult atopic dermatitis: a consensus by the Italian Society of Dermatology and Venereology (SIDeMaST), the Association of Italian Territorial and Hospital Allergists and Immunologists (AAIITO), the Italian Association of Hospital Dermatologists (ADOI), the Italian Society of Allergological, Environmental and Occupational Dermatology (SIDAPA), and the Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC).
Costanzo A, Amerio P, Asero R, Chiricozzi A, Corazza M, Cristaudo A, Cusano F, Ferrucci SM, Nettis E, Patrizi A, Patruno C, Peris K, Picozza M, Stingeni L, Girolomoni G; Italian AD Study Group. Costanzo A, et al. Ital J Dermatol Venerol. 2022 Feb;157(1):1-12. doi: 10.23736/S2784-8671.21.07129-2. Epub 2021 Dec 21. Ital J Dermatol Venerol. 2022. PMID: 34929995 Free article.
846 results